Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs

Vaccine

Volumn 27, Issue 16, 2009, Pages 2258-2264

  Kyriakis, Constantinos S ^a   De Vleeschauwer, Annebel ^a   Barbé, Filip ^a   Bublot, Michel ^b   Van Reeth, Kristien ^a  

^a GHENT UNIVERSITY   (Belgium)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

H5N1 avian influenza virus; Pigs; Pox vector vaccines

Indexed keywords

AVIAN INFLUENZA VACCINE; HEMAGGLUTININ; INACTIVATED VACCINE; LIPOPOLYSACCHARIDE;

ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; BACTERIAL GENE; BIRD DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOWL; HEMAGGLUTINATION; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H5N2; LUNG LOBE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SWINE; VACCINATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; POXVIRIDAE; SWINE; VACCINATION; VACCINES, SYNTHETIC;

EID: 61849120205     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.006     Document Type: Article

References (43)

1. World Health Organization (WHO). Epidemic and pandemic alert and response 2009. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1). Reported to WHO. Available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_01_24/en/index.html [accessed 24.01.09].
2. de Jong M.D., and Hien T.T. Avian influenza A (H5N1). J Clin Virol 35 (2006) 2-13
3. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351
4. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
5. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991-997
6. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
7. Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., and Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2 (2008) e1665
8. Taylor J., and Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6 (1998) 497-503
9. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 93 (1996) 11349-11353
10. Drexler I., Staib C., and Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol 15 (2004) 506-512
11. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., and Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 25 (2007) 5606-5612
12. Karaca K., Swayne D.E., Grosenbaugh D., Bublot M., Robles A., Spackman E., et al. Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 11 (2005) 1340-1342
13. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195 (2007) 1598-15606
14. Van Reeth K., Nauwynck H., and Pensaert M. Bronchoalveolar interferon-alpha, tumor necrosis factor-alpha, interleukin-1, and inflammation during acute influenza in pigs: a possible model for humans?. J Infect Dis 177 (1998) 1076-1079
15. van der Laan J.W., Herberts C., Lambkin-Williams R., Boyers A., Mann A.J., and Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 7 (2008) 783-793
16. Li H., Yu K., Yang H., Xin X., Chen J., Zhao P., et al. Isolation and characterization of H5N1 and H9N2 influenza viruses from pigs in China. Chin J Prev Vet Med 26 (2004) 1-6 (in Chinese)
17. Shi W.F., Gibbs M.J., Zhang Y.Z., Zhang Z., Zhao X.M., Jin X., et al. Genetic analysis of four porcine avian influenza viruses isolated from Shandong, China. Arch Virol 153 (2008) 211-217
18. Choi Y.K., Nguyen T.D., Ozaki H., Webby R.J., Puthavathana P., Buranathal C., et al. Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J Virol 79 (2004) 10821-10825
19. Shortridge K.F., Zhou N.N., Guan Y., Gao P., Ito T., Kawaoka Y., et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 252 (1998) 331-342
20. Lipatov A.S., Kwon Y.K., Sarmento L.V., Lager K.M., Spackman E., Suarez D.L., et al. Domestic pigs have low susceptibility to H5N1 highly pathogenic avian influenza viruses. PLoS Pathog 4 (2008) e1000102
21. De Vleeschauwer A., Barbe F., and Van Reeth K. Pathogenesis of low pathogenic H5N2 avian influenza virus in pigs. Proceedings of the 5th international symposium on emerging and re-emerging pig diseases. Krakow, Poland (2007) p241
22. World Health Organization. Global influenza program surveillance network evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11 (2005) 1515-1521
23. Brooks B.W., and Richmond H.N. Dynamics of liquid liquid-phase inversion using non-ionic surfactants. Colloids Surf 58 (1991) 131-148
24. Bublot M. Unpublished data; 2008.
25. Suarez D.L., Perdue M.L., Cox N., Rowe T., Bender C., Huang J., et al. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol 72 (1998) 6678-6688
26. Smith G, Guan Y, Peiris M, Kandun IN, Soendoro T, Sedyaningsih ER. Direct Submission. Submitted to Genbank; 2007.
27. Altschul S.F., Madden T.L., Schäffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25 (1997) 3389-3402
28. De Vleeschauwer A., Loeffen W., and Van Reeth K. Horse erythrocytes increase the sensitivity of the haemagglutination inhibition test to detect avian influenza antibodies in pigs. Proceedings of the 5th international symposium on emerging and re-emerging pig diseases. Krakow, Poland (2007) p 258
29. Palmer DF, Coleman MT, Dowdle WR, Schild GC. Advanced laboratory techniques for influenza diagnosis. US Department of Health, Education and Welfare Immunology; 1975. No. 6.
30. Van Reeth K., Gregory V., Hay A., and Pensaert M. Protection against a European H1N2 swine influenza virus in pigs previously infected with H1N1 and/or H3N2 subtypes. Vaccine 21 (2003) 1375-1381
31. Reed L.J., and Münch H. A simple method of estimating fifty per cent endpoints. Am J Hygiene 27 (1938) 493-497
32. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9 (1991) 190-193
33. Li K.S., Guan Y., Wang J., Smith G.J., Xu K.M., Duan L., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430 (2004) 209-213
34. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C., et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 77 (1998) 1230-1246
35. Hörig H., Lee D.S., Conkright W., Divito J., Hasson H., LaMare M., et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7,1 co-stimulatory molecule. Cancer Immunol Immunother 49 (2000) 504-514
36. Hel Z., Tsai W.P., Thornton A., Nacsa J., Giuliani L., Tryniszewska E., et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 167 (2001) 7180-7191
37. Santra S., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., Lord C.I., et al. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. J Immunol 168 (2002) 1847-1853
38. Townsend A.R., and Skehel J.J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 1602 (1984) 552-563
39. Yewdell J.W., Bennink J.R., Smith G.L., and Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82 (1985) 1785-1789
40. de Boer G.F., Back W., and Osterhaus A.D. An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol 115 (1990) 47-61
41. Alexander D.J., and Spackman D. Characterisation of influenza A viruses isolated from turkeys in England during March-May 1979. Avian Pathol 10 (1981) 281-293
42. Alexander D.J., Allan W.H., and Parsons G. Characterisation of influenza viruses isolated from turkeys in Great Britain during 1963-1977. Res Vet Sci 26 (1979) 17-20
43. El Garch H., Minke J.M., Rehder J., Richard S., Edlund Toulemonde C., Dinic S., et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol 123 (2008) 230-239